Stockscreener 앱 받기
43.78
2.17%
0.93
시간 외 거래:
43.80
0.02
+0.05%
전일 마감가:
$42.85
열려 있는:
$42.86
하루 거래량:
1.55M
Relative Volume:
0.86
시가총액:
$6.98B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-14.40
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
+5.14%
1개월 성능:
+4.24%
6개월 성능:
+41.04%
1년 성능:
-6.18%
1일 변동 폭
$42.80
$43.82
1주일 범위
$40.37
$43.82
52주 변동 폭
$23.95
$50.43
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
43.78 | 6.83B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
What technical models suggest about Ionis Pharmaceuticals Inc.’s comebackJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
How to use Fibonacci retracement on Ionis Pharmaceuticals Inc.July 2025 Final Week & Weekly Top Performers Watchlists - Newser
Vanguard Group Inc. Has $494.30 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals Inc. stock chart pattern explained2025 Fundamental Recap & Risk Controlled Stock Alerts - Newser
Ionis Pharmaceuticals (NASDAQ:IONS) Given “Neutral” Rating at UBS Group - Defense World
Ionis Pharmaceuticals (IONS) – Investment Analysts’ Weekly Ratings Changes - Defense World
UBS Group Reaffirms “Neutral” Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals shares rise 1.16% premarket after UBS raised its price target to $46. - AInvest
Institutional scanner results for Ionis Pharmaceuticals Inc.Recession Risk & Low Risk Entry Point Tips - Newser
Stocks Flashing Renewed Technical Strength: Ionis Pharmaceuticals - Investor's Business Daily
Ionis Pharmaceuticals Inc. Hits Price Floor — Bounce IncomingLow Capital High Return Stock Plans Reviewed - 선데이타임즈
UBS Reiterates Hold Rating for Ionis Pharmaceuticals with $46 Price Target - AInvest
Ionis Pharmaceuticals Gets Neutral Rating from UBS with $46 Price Target - AInvest
Ionis Pharmaceuticals (IONS) Analyst Rating Update by UBS | IONS Stock News - GuruFocus
Ionis Pharmaceuticals: UBS Raises PT to $46, Maintains Neutral Rating - AInvest
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Trend analysis for Ionis Pharmaceuticals Inc. this weekSmart Trade Mapping with Entry Details - Newser
Will Ionis Pharmaceuticals' (IONS) Return to Profitability and Raised Guidance Shift Its Investment Narrative? - simplywall.st
Q3 EPS Estimate for Ionis Pharmaceuticals Reduced by Analyst - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Envestnet Asset Management Inc. - Defense World
Insider Transactions Reported | Ionis Pharmaceuticals(IONS)saw insider trading activity on 8/6/2025 - AInvest
Ionis Pharmaceuticals EVP Geary Richard S sells 10,000 shares at $42.86/share on August 5. - AInvest
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ionis Pharmaceuticals Inc. stock momentum explainedWeekly Hot Stocks Based on Volume Flow - Newser
Ionis Pharma EVP Schneider sells $408,701 in stock By Investing.com - Investing.com South Africa
Hereditary Transthyretin Amyloidosis (hATTR) Pipeline - openPR.com
Ionis Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Ionis Pharmaceuticals (IONS): Morgan Stanley Upgrade and Future ProspectsNews and Statistics - IndexBox
Ionis Pharmaceuticals Inc. Stock Lags Behind Sector BenchmarksHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru
Why Morgan Stanley Upgraded This Biotech Stock to a Buy - Yahoo Finance
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency - MSN
What analysts say about Ionis Pharmaceuticals Inc. stockBreakout profit opportunities - Jammu Links News
How does Ionis Pharmaceuticals Inc. compare to its industry peersGet exclusive access to expert stock recommendations - Jammu Links News
What are Ionis Pharmaceuticals Inc. company’s key revenue driversFree Popular Stock Recommendations - Jammu Links News
What institutional investors are buying Ionis Pharmaceuticals Inc. stockCapitalize on market momentum for maximum gains - Jammu Links News
Ionis Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Is it the right time to buy Ionis Pharmaceuticals Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
Why is Ionis Pharmaceuticals Inc. stock attracting strong analyst attentionAchieve breakthrough profits with expert advice - Jammu Links News
Is Ionis Pharmaceuticals Inc. a growth stock or a value stockMarket-crushing profits - Jammu Links News
Ionis raises 2025 revenue guidance to $850M with Tryngolza momentum and Donidalorsen launch on track - MSN
How volatile is Ionis Pharmaceuticals Inc. stock compared to the marketCapital growth strategies that work - Jammu Links News
What makes Ionis Pharmaceuticals Inc. stock price move sharplyBuild wealth with high-performing stocks - Jammu Links News
What are analysts’ price targets for Ionis Pharmaceuticals Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
Ionis Pharmaceuticals (NASDAQ:IONS) Earns “Buy” Rating from HC Wainwright - Defense World
What is Ionis Pharmaceuticals Inc. company’s growth strategyUnprecedented profits - Jammu Links News
What catalysts could drive Ionis Pharmaceuticals Inc. stock higher in 2025Invest confidently with professional advice - Jammu Links News
When is Ionis Pharmaceuticals Inc. stock expected to show significant growthBuild a winning portfolio with smart picks - Jammu Links News
Is Ionis Pharmaceuticals Inc. stock overvalued or undervaluedUnlock powerful market insights for success - Jammu Links News
HC Wainwright Reiterates “Buy” Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals Inc. Stock Analysis and ForecastGet professional advice for portfolio optimization - Jammu Links News
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ionis Pharmaceuticals Inc 주식 (IONS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Geary Richard S | EVP, Chief Development Officer |
Aug 05 '25 |
Sale |
42.86 |
10,000 |
428,593 |
89,492 |
0.41%
0.88%
자본화:
|
볼륨(24시간):